Research based on a nationally representative survey of 100 US healthcare providers who treat sickle cell disease patients has identified a significant gap between the availability of red blood cell exchange therapy and its actual utilization. The procedure, which removes damaged red blood cells from patients and replaces them with donor red blood cells while preserving the patient’s own plasma, platelets, and white blood cells, is offered by most surveyed providers but used by fewer than 3% of their patients.
Multiple barriers prevent wider adoption of the treatment, according to the study. Healthcare providers cited coordination challenges between different medical departments, insufficient supplies of donated blood, and insufficient familiarity with the procedure as the most common obstacles. Only 5% of surveyed providers reported having no barriers to delivering this therapy. From the patient perspective, insurance coverage emerged as a major concern affecting access to red blood cell exchange.
Sickle cell disease affects more than 100,000 people in the United States and approximately 8 million globally, with the condition disproportionately impacting people of color. The disease involves an inherited hemoglobin disorder that causes red blood cells to assume a crescent or sickle shape, reducing their flexibility and potentially blocking blood flow throughout the body. Among those diagnosed, 90% identify as non-Hispanic Black or African American, while an estimated 3%-9% identify as Hispanic or Latino.
Experts attributed access disparities to systemic factors including the geographic distribution of comprehensive sickle cell treatment centers, socioeconomic vulnerabilities affecting approximately 80% of patients who rely on Medicaid, and limited awareness among both patients and providers about available treatment options. Rural populations face particular disadvantages due to equipment scarcity and difficulty maintaining specialized staff competencies at smaller facilities. Researchers and clinicians emphasized the need for expanded networks of comprehensive sickle cell disease centers and improved coordination among hematologists, transfusion specialists, and other support services to make these therapies more widely accessible.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI